• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Arnold Mitchell

    12/26/23 5:06:56 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTPI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Arnold Mitchell

    (Last) (First) (Middle)
    1185 AVENUE OF THE AMERICAS, 3RD FLOOR

    (Street)
    NEW YORK NY 10036

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Petros Pharmaceuticals, Inc. [ PTPI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    12/21/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.41 12/21/2023 A 20,000 (1) 12/21/2033 Common Stock 20,000 $0 20,000 D
    Explanation of Responses:
    1. The stock options vested 100% upon grant.
    Remarks:
    Vice Pres. of Finance & Chief Acc. Off.
    /s/ Mitchell Arnold 12/26/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PTPI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTPI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Walker Wayne Remell was granted 150,000 shares, increasing direct ownership by 1,804% to 158,314 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    2/21/25 5:36:07 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Arnold Mitchell was granted 150,000 shares (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    2/21/25 5:34:57 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Silverman Joshua was granted 1,000,000 shares, increasing direct ownership by 8,899% to 1,011,237 units (SEC Form 4)

    4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)

    2/21/25 5:33:12 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

    Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces its conducive position in connection with the recently issued final rule, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" ("ACNU") by the United States Food and Drug Administration (the "FDA") for companies seeking Rx-to-OTC switch for pharmaceutical products. The Comp

    1/7/25 9:15:00 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

    Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / December 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a prospective Rx-to-OTC switch solution across a multitude of conditions and existing Rx only therapies. If this Software as a Service ("SaaS") and S

    12/17/24 9:00:00 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

    Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology ("App Comp"), which has unique differences from the current Drug Facts Label ("DFL"). Of the 31 objectives, 29 scored >90% comprehension Point Estimate ("PE"), 30 scored >86.7% comprehension PE, and all scored >80% compreh

    9/11/24 9:15:00 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTPI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.

    SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    8/15/25 8:00:57 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Petros Pharmaceuticals Inc.

    10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

    8/14/25 4:08:04 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Petros Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)

    6/20/25 5:20:52 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTPI
    Leadership Updates

    Live Leadership Updates

    View All

    Oblong Appoints Two New Directors to its Board

    Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor

    5/30/23 8:00:00 AM ET
    $OBLG
    $PMCB
    $PTPI
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/13/24 11:14:05 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Petros Pharmaceuticals Inc.

    SC 13G - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    2/14/24 3:38:38 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTPI
    Financials

    Live finance-specific insights

    View All

    The Urvan Group Issues Letter to AMMO Inc. Shareholders Regarding its Nomination of a Full Slate of Highly Qualified Candidates for Election to the Company's Board of Directors

    Delivers Overview of New Strategy for Leveraging AMMO's Existing Assets and Evolving the Company into a Diversified, Growing and Profitable Ecommerce Powerhouse    Highlights Long-Term Opportunity to Achieve $1 Billion in Annual Sales with Strong Cash Flows and Sustainable Margins, Resulting in Superior Value Creation for Shareholders Introduces Diverse Slate with Expertise in Corporate Governance, Ecommerce, Finance, M&A and Strategic Growth Across Relevant B2B and B2C Categories Steven Urvan (together with the other participants in his solicitation, the "Urvan Group" or "we"), who owns approximately 17.1% of the outstanding common shares of AMMO, Inc. (NASDAQ:POWW) ("AMMO" or the "Co

    8/29/22 8:05:00 AM ET
    $AYRO
    $CLAR
    $DD
    Telecommunications Equipment
    Consumer Discretionary
    Recreational Games/Products/Toys
    Major Chemicals

    Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights

    NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces financial results for the fiscal year ended December 31, 2021. Recent Corporate Highlights: Entered collaboration with Dr. Drew Pinsky to bring awareness to men's health with a focus on driving awareness around erectile and other sexual dysfunctionsPartnered with leading global contract manufacturer to bring production of erectile dysfunction drug STENDRA® to the United StatesLaunched two self-selection studies for erectile dysfunction drug STENDRA®Announced positive over-the-counter (OTC) label compr

    4/1/22 7:00:00 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care